Get notified when IONS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIonis reports Q2 2026 results with TRYNGOLZA launch momentum, Angelman Phase 3 enrollment complete
Filed July 29, 2026 · Period ending July 29, 2026 · ~1 min read
Key Changes
-
high
CARDIO-TTRansform Phase 3 trial of eplontersen for ATTR-CM missed primary endpoint in overall population, though showed nominal significance in monotherapy subgroup; results to be presented at ESC Congress August 2026.
Exhibit 99.1 view on EDGAR → -
high
TRYNGOLZA generated $5M Q2 sales and $32M first-half sales; company on track for $100-110M full-year 2026 sales, with sHTG launch showing early momentum following June 2026 FDA approval.
Exhibit 99.1 view on EDGAR → -
high
DAWNZERA generated $26M Q2 sales (up 63% vs Q1) and $42M first-half sales; company on track for $110-120M full-year 2026 sales.
Exhibit 99.1 view on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ESI 10-Q) is open in full — no account needed.
Partner
Trade IONS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jul 30, 2026 · How we verify